Elucidating the exact pharmacological mechanism of action (MOA) of Normally taking place compounds can be tough. Though Tarselli et al. (60) produced the 1st de novo synthetic pathway to conolidine and showcased this naturally occurring compound effectively suppresses responses to both of those chemically induced and inflammation-derived suffering,